A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

Summary

A 12-week Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects with Familial Mediterranean Fever followed by an additional Open-label Extension Phase.

Timeline

Start

2022-09-13

Primary completion

2023-11-30

Completion

2024-12-30

Drugs

Indications